rufinamide
E939682
Rufinamide is an anticonvulsant medication primarily used to help control seizures in patients with Lennox-Gastaut syndrome.
All labels observed (1)
| Label | Occurrences |
|---|---|
| rufinamide canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T11698352 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: rufinamide Context triple: [Lennox-Gastaut syndrome, treatedWith, rufinamide]
-
A.
topiramate
Topiramate is an anticonvulsant medication commonly used to treat various forms of epilepsy and prevent migraines.
-
B.
lamotrigine
Lamotrigine is an anticonvulsant medication primarily used to treat epilepsy and bipolar disorder by stabilizing neuronal activity and reducing the frequency of seizures or mood episodes.
-
C.
Namenda
Namenda is a prescription medication used to treat moderate to severe Alzheimer's disease by regulating the activity of glutamate in the brain.
-
D.
carbamazepine
Carbamazepine is an anticonvulsant and mood-stabilizing drug commonly used to treat epilepsy, trigeminal neuralgia, and bipolar disorder.
-
E.
Epidiolex
Epidiolex is a prescription cannabidiol-based medication used to treat certain rare and severe forms of epilepsy.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: rufinamide Target entity description: Rufinamide is an anticonvulsant medication primarily used to help control seizures in patients with Lennox-Gastaut syndrome.
-
A.
topiramate
Topiramate is an anticonvulsant medication commonly used to treat various forms of epilepsy and prevent migraines.
-
B.
lamotrigine
Lamotrigine is an anticonvulsant medication primarily used to treat epilepsy and bipolar disorder by stabilizing neuronal activity and reducing the frequency of seizures or mood episodes.
-
C.
Namenda
Namenda is a prescription medication used to treat moderate to severe Alzheimer's disease by regulating the activity of glutamate in the brain.
-
D.
carbamazepine
Carbamazepine is an anticonvulsant and mood-stabilizing drug commonly used to treat epilepsy, trigeminal neuralgia, and bipolar disorder.
-
E.
Epidiolex
Epidiolex is a prescription cannabidiol-based medication used to treat certain rare and severe forms of epilepsy.
- F. None of above. chosen
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
anticonvulsant drug
ⓘ
antiepileptic drug ⓘ pharmaceutical compound ⓘ |
| hasATCCode | N03AF03 ⓘ |
| hasBioavailability | increased with food ⓘ |
| hasBrandName |
Banzel
NERFINISHED
ⓘ
Inovelon NERFINISHED ⓘ |
| hasCASNumber | 106308-44-5 ⓘ |
| hasChemicalFormula | C10H8F2N4O ⓘ |
| hasCommonAdverseEffect |
dizziness
ⓘ
fatigue ⓘ headache ⓘ loss of appetite ⓘ nausea ⓘ somnolence ⓘ vomiting ⓘ |
| hasContraindication | familial short QT syndrome ⓘ |
| hasDeveloper | Eisai Co., Ltd. NERFINISHED ⓘ |
| hasDrugInteraction |
CYP3A4 inducers
ⓘ
oral contraceptives ⓘ valproic acid ⓘ |
| hasEffect | reduction of seizure frequency ⓘ |
| hasEliminationHalfLife | approximately 6 to 10 hours ⓘ |
| hasFDAApprovalYear | 2008 ⓘ |
| hasIUPACName | 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide ⓘ |
| hasMechanismOfAction |
modulation of voltage-gated sodium channels
ⓘ
prolongation of the inactive state of sodium channels ⓘ |
| hasMolarMass | 238.19 g/mol ⓘ |
| hasPregnancyCategory | Category C (US, historical) ⓘ |
| hasPrimaryMetabolismSite | liver ⓘ |
| hasProteinBinding | approximately 34 percent ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasSeriousAdverseEffect |
multiorgan hypersensitivity reactions
ⓘ
status epilepticus ⓘ suicidal ideation ⓘ |
| hasTargetPopulation |
adult patients with Lennox-Gastaut syndrome
ⓘ
patients with Lennox-Gastaut syndrome ⓘ pediatric patients with Lennox-Gastaut syndrome ⓘ |
| hasWarning |
risk of QT interval shortening
ⓘ
risk of suicidal behavior and ideation ⓘ |
| isAdministeredAs |
oral suspension
ⓘ
oral tablet ⓘ |
| isExcretedVia | kidney ⓘ |
| isIndicatedFor |
Lennox-Gastaut syndrome
NERFINISHED
ⓘ
adjunctive treatment of seizures ⓘ |
| isMetabolizedBy | carboxylesterases ⓘ |
| isPrescriptionOnly | true ⓘ |
| isTakenWithFood | recommended ⓘ |
| isUsedFor | treatment of seizures associated with Lennox-Gastaut syndrome ⓘ |
| wasApprovedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: rufinamide Description of subject: Rufinamide is an anticonvulsant medication primarily used to help control seizures in patients with Lennox-Gastaut syndrome.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.